Manufacturer of Controlled Substances; Notice of Registration; Halo Pharmaceutical, Inc., 4974 [2014-01785]
Download as PDF
<![CDATA[
4974
Federal Register / Vol. 79, No. 20 / Thursday, January 30, 2014 / Notices
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Dated: January 16, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Halo Pharmaceutical, Inc.
Manufacturer of Controlled
Substances; Notice of Registration;
Chattem Chemicals, Inc.
By Notice dated August 14, 2013, and
published in the Federal Register on
August 20, 2013, 78 FR 51210, Halo
Pharmaceutical, Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
By Notice dated August 14, 2013, and
published in the Federal Register on
August 20, 2013, 78 FR 51210, Chattem
Chemicals, Inc., 3801 St. Elmo Avenue,
Chattanooga, Tennessee 37409, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
[FR Doc. 2014–01707 Filed 1–29–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Importer of Controlled Substances;
Notice of Registration; Clinical
Supplies Management, Inc.
By Notice dated August 29, 2013, and
published in the Federal Register on
September 6, 2013, 78 FR 54913,
Clinical Supplies Management, Inc., 342
42nd Street South, Fargo, North Dakota
58103, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites, conducting FDAapproved clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Supplies Management, Inc., to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Clinical Supplies Management, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 14, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Drug
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–01785 Filed 1–29–14; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
18:24 Jan 29, 2014
Jkt 232001
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone
and is not for commercial distribution.
The company plans to manufacture
Hydromorphone for sale to other
manufacturers and to manufacture other
controlled substances for distribution to
its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of Halo
Pharmaceutical, Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Halo Pharmaceutical, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
[FR Doc. 2014–01788 Filed 1–29–14; 8:45 am]
VerDate Mar<15>2010
PO 00000
Frm 00111
Fmt 4703
Schedule
Schedule
Sfmt 4703
Gamma
Hydroxybutyric
Acid
(2010).
4-Methoxyamphetamine (7411) ...
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers. Regarding (9640), the
company plans to manufacture another
controlled substance for sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Chattem Chemicals, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Chattem Chemicals, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 79, Number 20 (Thursday, January 30, 2014)]
[Notices]
[Page 4974]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-01785]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Halo Pharmaceutical, Inc.
By Notice dated August 14, 2013, and published in the Federal
Register on August 20, 2013, 78 FR 51210, Halo Pharmaceutical, Inc., 30
North Jefferson Road, Whippany, New Jersey 07981, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
Dihydromorphine is an intermediate in the manufacture of
Hydromorphone and is not for commercial distribution.
The company plans to manufacture Hydromorphone for sale to other
manufacturers and to manufacture other controlled substances for
distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Halo Pharmaceutical, Inc., to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Halo Pharmaceutical, Inc., to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-01785 Filed 1-29-14; 8:45 am]
BILLING CODE 4410-09-P
